Press Releases

Press Releases

    Date Title View
    11/13/19
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Conferences
    PDF Version
    11/11/19
    Summary ToggleData from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes
    PDF Version
    11/08/19
    Summary ToggleThe Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace
    PDF Version
    11/06/19
    Summary ToggleHorizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
    11/05/19
    Summary ToggleHorizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
    PDF Version
    11/04/19
    Summary ToggleClinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
    PDF Version
    11/04/19
    Summary ToggleNew Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting
    PDF Version
    10/31/19
    Summary ToggleIntegrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
    PDF Version
    10/24/19
    Summary ToggleHorizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
    PDF Version
    10/24/19
    Summary ToggleNew Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting
    PDF Version
    Displaying 1 - 10 of 472 results